학술논문
Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy
Document Type
Article
Author
Othman, J.; Potter, N.; Dillon, R.; Russell, N.H.; Tiong, I.S.; Loo, S.; Wei, A.H.; Ivey, A.; Fong, C.Y.; O'Nions, J.; Chan, W.Y.; Sellar, R.; Dennis, M.; Elliot, J.; Mokretar, K.; Austin, M.; Gallipoli, P.; Latif, A.-L.; Amer, M.; Crawley, C.; Crolla, F.; Cross, J.; Mehta, P.; Dang, R.; Galli, S.; Hogan, F.; Kalkur, P.; Khan, A.; Krishnamurthy, P.; Laurie, J.; Marshall, S.; Murthy, V.; Nagumantry, S.; Pillai, S.; Taylor, T.; Zhao, R.
Source
In: Blood . (Blood, 25 January 2024, 143(4):336-341)
Subject
Language
English
ISSN
15280020
00064971
00064971